Denali Therapeutics announced program progress and expected milestones for 2024. Tividenofusp alfa: MPS II: 2024 expected progress and milestones: Complete enrollment of global Phase 2/3 COMPASS study in MPS II; Presentation of additional interim Phase 1/2 data at WORLDSymposium and at the Society for the Study of Inborn Errors of Metabolism Annual Symposium. DNL343: ALS: 2024 expected progress and milestones: Complete enrollment of participants in Regimen G in Phase 2/3 HEALEY ALS Platform Trial. SAR443820/DNL788: ALS, MS: 2024 expected progress and milestones: Sanofi to announce topline results from the Phase 2 HIMALAYA study in ALS in the first half of 2024; Continue K2 Phase 2 study in MS. BIIB122/DNL151: Parkinson’s disease: 2024 expected progress and milestones: Continue Phase 2b LUMA study in early-stage Parkinson’s disease. Eclitasertib UC: 2024 expected progress and milestones: Continue Phase 2 UC study. TAK-594/DNL593: Frontotemporal Dementia-Granulin: 2024 expected progress and milestones: Continue Part B of the Phase 1/2 study in FTD-GRN. DNL126: MPS IIIA: 2024 expected progress and milestones:Biomarker proof of concept and safety data from the Phase 1/2 study by the end of 2024
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DNLI:
